hepatitis: Post-transfusion hepatitis: impact of non-A, non-B hepatitis...
In pmlr: Penalized Multinomial Logistic Regression

Data from a randomized double-blind trial to assess whether withholding donor blood positive for the non-A, non-B (NANB) surrogate markers would reduce the frequency of post-transfusion hepatitis. The dataset contains 4,588 subjects enrolled from 1988 to 1992 into two study groups that received allogenic blood from which units positive for NANB surrogate markers were withheld (n=2,311) or not withheld (n=2,277). Subjects were followed up for 6 months and assessed for the presence of post-transfusion hepatitis.

1	data(hepatitis)

A data frame with 28 rows and the following 6 columns:

city: Subjects were recruited from 3 Canadian Red Cross Society Blood Centres and 13 university-affiliated hopsitals in 3 cities: Toronto, Hamilton and Winnipeg.
group: Eligible subjects were assigned to one of two allogenic blood recipient groups. One group received products that had only routine Canadian transfusion-transmissible disease marker screening (no-withhold). The other group received only products that were not positive for NANB surrogate markers (withhold).
time: Hepatitis C (HCV) screening was introduced in Canada in May, 1990. Subjects were recruited into the study before (pre) and after (post) the introduction of anti-HCV testing.
HCV: Post-transfusion HCV hepatitis present (1) or absent (0).
nonABC: Post-transfusion non-A, non-B, non-C hepatitis present (1) or absent (0)
counts: Number of subjects

Blajchman M. A., Bull, S. B. and Feinman S. V. for the Canadian Post-Transfusion Hepatitis Prevention Study Group (1995) Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. The Lancet, 345, 21–25.

pmlr documentation built on May 30, 2017, 7:48 a.m.